公开(公告)号：US20200062442A1

公开(公告)日：2020-02-27

申请号：US16467730

申请日：2018-01-05

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Takahisa Sakaguchi

IPC: B65D5/66 ,  A61J1/03 ,  A61J1/16

Abstract: Provided is a container including a main body, a lid body, and a fixing mechanism that fixes the lid body to prevent the lid body from opening from the main body when the lid body is closed, the fixing being released when the lid body moves to a front side with respect to the main body. Cutouts are formed in side plates of the main body. The container is configured such that, by a rear plate tilting forward toward the cutouts of the side plates, the lid body moves to the front side with respect to the main body and the fixing of the lid body is released, and as the rear plate and a top plate of the lid body form a single plane, the top plate rises and the lid body opens.

公开(公告)号：US10537612B2

公开(公告)日：2020-01-21

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  A61K47/02

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations.The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.

公开(公告)号：US20190388420A1

公开(公告)日：2019-12-26

申请号：US16465277

申请日：2018-02-06

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoichi Ozawa ,  Yusaku Hori ,  Kazuhiko Yamada ,  Hiroshi Kamiyama ,  Masahiro Matsuki

IPC: A61K31/4985 ,  A61P35/00

Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.

公开(公告)号：US20190337921A1

公开(公告)日：2019-11-07

申请号：US16349508

申请日：2017-11-22

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark Bock ,  Ming-Hong Hao ,  Manav Korpal ,  Vijay Kumar Nyavanandi ,  Xiaoling Puyang ,  Susanta Samajdar ,  Peter Gerard Smith ,  John Wang ,  Guo Zhu Zheng ,  Ping Zhu ,  Lorna Helen Mitchell ,  Nicholas Larsen ,  Nathalie Rioux

IPC: C07D401/06 ,  C07D209/08 ,  C07D401/14 ,  A61P35/00

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：US10428140B2

公开(公告)日：2019-10-01

申请号：US15753611

申请日：2016-09-06

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryota Taguchi ,  Toshio Imai ,  Eiji Inoue ,  Akio Yamada ,  Aki Nakatani ,  Toshifumi Hirayama ,  Yuichi Ono ,  Shunsuke Ito

IPC: A61K39/00 ,  A61P21/02 ,  A61P25/28 ,  C07K16/28 ,  C12N15/62

Abstract: It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.

公开(公告)号：US10407439B2

公开(公告)日：2019-09-10

申请号：US15906401

申请日：2018-02-27

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Francis G. Fang ,  Hyeong-Wook Choi ,  Silvio Campagna ,  Steven Mathieu

IPC: C07D493/22 ,  C07D493/08 ,  C07D493/18 ,  C07B57/00 ,  C07D313/00

Abstract: The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.

公开(公告)号：US10407393B2

公开(公告)日：2019-09-10

申请号：US16229805

申请日：2018-12-21

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Taiju Nakamura ,  Taichi Abe ,  Yusuke Miyashita ,  Hirofumi Kuroda ,  Yusuke Ayata ,  Atsushi Akao

IPC: C07D215/48 ,  A61K31/47

Abstract: Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.

公开(公告)号：US20190231720A1

公开(公告)日：2019-08-01

申请号：US16260350

申请日：2019-01-29

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Keigo Tanaka ,  Tasuku Ishida ,  Masayuki Miyano ,  Raku Shinkyo

IPC: A61K31/166 ,  A61P19/10 ,  A61P29/00 ,  A61P7/06

CPC classification number: A61K31/166 ,  A61P7/06 ,  A61P19/10 ,  A61P29/00 ,  C07C233/73 ,  C07C235/60

Abstract: The present invention provides a compound represented by formula (1): or pharmaceutically acceptable salt thereof, wherein X and Y are the same or different from each other and represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with a C1-6 alkoxy group, and Z and W are the same or different from each other and represent a hydrogen atom, a halogen atom, or a C1-6 alkyl group.

公开(公告)号：US20190142819A1

公开(公告)日：2019-05-16

申请号：US16092245

申请日：2017-04-17

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Alton Kremer

IPC: A61K31/472 ,  A61K9/20 ,  A61K31/436 ,  A61P35/00 ,  A61K9/48

Abstract: Methods and compositions for treating a renal cell carcinoma with the combination of lenvatinib or a pharmaceutically acceptable salt thereof and everolimus are provided. Particularly useful dosages and dose modifications upon the occurrence of adverse events are also provided.

公开(公告)号：US20190111043A1

公开(公告)日：2019-04-18

申请号：US16225772

申请日：2018-12-19

Applicant: NATIONAL CANCER CENTER ,  Eisai R&D Management Co., Ltd.

Inventor： Tatsuhiro SHIBATA ,  Yasuhito ARAI ,  Kenichi NOMOTO ,  Tomio NAKAMURA ,  Akihiko TSURUOKA ,  Saori MIYANO

IPC: A61K31/4545

Abstract: The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.